From: Rectal-sparing type of ulcerative colitis predicts lack of response to pharmacotherapies
Risk Factors | OR(95% CI) | p-value |
---|---|---|
Age at initial surgery <44 years | 1.94(0.93-4.17) | 0.08 |
Duration of disease(month) < 70 months | 2.45(1.10-5.54) | 0.03* |
Severe/Fuluminant disease | 87.1(40.9-205.1) | <0.01* |
Total given PSL dose <5000 mg | 3.02(1.39-6.76) | <0.01* |
Daily pre-operative PSL dose ≥9 mg/day | 2.59(1.20-5.65) | 0.02* |
Immunomodulators administration (AZA/6-MP) | 0.68(0.26-1.69) | 0.41 |
Rectal sparing type | 5.59(1.90-16.9) | <0.01* |